2010
Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors
Sawyer AJ, Saucier-Sawyer JK, Booth CJ, Liu J, Patel T, Piepmeier JM, Saltzman WM. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Delivery And Translational Research 2010, 1: 34-42. PMID: 21691426, PMCID: PMC3117592, DOI: 10.1007/s13346-010-0001-3.Peer-Reviewed Original ResearchConvection-enhanced deliveryUnloaded nanoparticlesNanoparticle treatmentPolymer nanoparticlesNanoparticlesRelease nanoparticlesDrug loadingDrug releasePolymer deliveryDirect deliveryIntracranial tumorsSimultaneous controlIntracranial 9L tumorsLong-term survivorsDelivery of chemotherapyDeliveryDiffusional penetrationLocal tissue toxicityMedian survivalChemotherapy agentsTherapeutic benefitGlioblastoma multiformeGliosarcoma cellsTissue toxicityTumorsPhase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, Group F. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†. Neuro-Oncology 2010, 12: 871-881. PMID: 20511192, PMCID: PMC2940677, DOI: 10.1093/neuonc/nop054.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsBrain NeoplasmsCarmustineCatheters, IndwellingConvectionDecanoic AcidsDrug Administration RoutesExotoxinsFemaleGlioblastomaHumansInterleukin-13Kaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPolyestersRecombinant Fusion ProteinsYoung AdultConceptsConvection-enhanced deliveryCintredekin besudotoxGliadel wafersMedian survivalTumor resectionGlioblastoma multiformeEfficacy-evaluable populationAdverse event profileHealth-related qualityPhase III evaluationTime of randomizationEvaluable populationTertiary endpointsPrimary endpointAdult patientsBaseline characteristicsFirst recurrenceOverall survivalPulmonary embolismActive comparatorTreatment armsIL13-PE38QQRIntraparenchymal catheterSurvival differencesGBM patients
2007
Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. Journal Of Clinical Oncology 2007, 25: 837-844. PMID: 17327604, DOI: 10.1200/jco.2006.08.1117.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryIntracerebral convection-enhanced deliveryCintredekin besudotoxRecurrent malignant gliomaMalignant gliomasGlioblastoma multiformeMedian survivalCatheter placementTumor resectionInfusion durationProcedure-related adverse eventsFavorable risk-benefit profilePhase I clinical studyBetter drug distributionDirect intracerebral deliveryOptimal drug distributionOverall median survivalPortion of patientsRisk-benefit profileDevastating brain tumorDrug distributionAdverse eventsHigh tissue concentrationsIntracerebral deliveryTumor necrosis
2006
New methods for direct delivery of chemotherapy for treating brain tumors.
Sawyer AJ, Piepmeier JM, Saltzman WM. New methods for direct delivery of chemotherapy for treating brain tumors. The Yale Journal Of Biology And Medicine 2006, 79: 141-52. PMID: 17940624, PMCID: PMC1994797.Peer-Reviewed Original ResearchConceptsConvection-enhanced deliveryBrain tumorsPrimary malignant brain tumorLocal deliveryBlood-brain barrierMalignant brain tumorsStandard chemotherapeutic drugsBrain cancer treatmentAnti-cancer therapyMedian survivalInfusion siteSevere formMalignant cellsNew delivery strategiesChemotherapy drugsChemotherapyDiagnostic imagingTumorsChemotherapeutic drugsCancer treatmentDrugsInvasive cellsSource of drugsDelivery strategiesBrain
1996
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain
Halperin E, Herndon J, Schold S, Brown M, Vick N, Cairncross J, Macdonald D, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, Salter M, Imperato J, Khandekar J, Paleologos N, Burger P, Bentel G, Friedman A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. International Journal Of Radiation Oncology • Biology • Physics 1996, 34: 793-802. PMID: 8598355, DOI: 10.1016/0360-3016(95)02025-x.Peer-Reviewed Original ResearchConceptsExternal beam radiotherapyKarnofsky performance statusMedian survivalSurvival benefitERT groupAnaplastic gliomasBeam radiotherapyMitomycin CVs. 11.4 monthsProportion of patientsSignificant survival benefitPossible survival benefitTreatment of adultsYears of ageBCNU groupPerformance statusProspective trialHistologic diagnosisMalignant gliomasMito groupStereotactic biopsyPatientsGreater riskFourth weekThird dayIn vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor.
Piepmeier J, Rabidou N, Schold S, Bitonti A, Prakash N, Bush T. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Research 1996, 56: 359-61. PMID: 8542592.Peer-Reviewed Original ResearchConceptsMalignant brain tumorsMedian survivalControl animalsAthymic miceBrain tumorsReductase inhibitorsHuman malignant brain tumorsHuman glioblastomaDays of treatmentSK-N-MCConcentration-dependent inhibitionTumor regressionIntracerebral implantsIntracerebral xenograftsXenograft modelGlioblastoma cell linesVivo inhibitionPotent antiproliferative activityNeuroblastomaGlioblastomaSurvivalCell linesXenograftsNanomolar concentrationsTumors